UroGen Pharma (URGN) Return on Sales (2017 - 2026)

UroGen Pharma (URGN) has reported Return on Sales for 10 consecutive years, with 0.0% the latest figure, recorded in Q1 2026.

• Quarterly Return on Sales rose 2.0% year-over-year to 0.0% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.01% (changed 0.0% YoY) and the FY2025 annual result came in at 0.01%, changed 0.0% from the prior year.
• Return on Sales retreated to 0.0% in Q1 2026 per URGN's latest filing, from 0.0% in the prior quarter.
• Over the last five years, Return on Sales for URGN reached as high as 0.0% in Q4 2025 and fell as low as 0.02% in Q1 2025.
• A 5-year average of 0.01% and a median of 0.01% in 2025 frame the typical range for Return on Sales.
• Annual changes were most pronounced in 2025 — Return on Sales dropped 1 bps — and 2026, when it advanced 2 bps.
• Year by year, Return on Sales stood at 0.0% in 2022, then soared by 118 bps to 0.0% in 2023, then sank by 1235 bps to 0.0% in 2024, then soared by 195 bps to 0.0% in 2025, then sank by 294 bps to 0.0% in 2026.
• According to Business Quant data, Return on Sales over the past three periods registered 0.0%, 0.0%, and 0.01% for Q1 2026, Q4 2025, and Q3 2025 respectively.